AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28692531 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-based ART
Number of subjects: 60
Study 28692531 — intervention group
Group type: COMPARATOR
Intervention: ART-naive
Number of subjects: 60
Study 25517202 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine chewing gum (3-4 mg · kg(‐1))
Number of subjects: 20
Study 25517202 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 20
Study 23418316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrajejunal taurocholic acid (TCA)
Number of subjects: 10
Study 23418316 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study 21078418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Group
Number of subjects: 0
Study 21078418 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 19348407 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 19348407 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 19348407 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic attitude of the nurse
Number of subjects: 0
Study 16432471 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens wear
Number of subjects: 484
Study 16432471 — intervention group
Group type: COMPARATOR
Intervention: Spectacle wear
Number of subjects: 484
Study 15319562 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage massage (MLD) in combination with multi-layered compression bandaging (CB)
Number of subjects: 50
Study 15319562 — intervention group
Group type: COMPARATOR
Intervention: Compression bandaging (CB) alone
Number of subjects: 50
Study 10922420 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg bolus intravenous injection followed by 8 mg per hour infusion for 72 hours, then 20 mg orally per day for 8 weeks)
Number of subjects: 240
Study 10922420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same treatment protocol as omeprazole but without the active drug)
Number of subjects: 240
Study 10922420 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 240
Study 10922420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 9314091 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily for 7 days
Number of subjects: 85
Study 9314091 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg per os twice a day
Number of subjects: 85
Study 7870968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine (0.25 mg/kg)
Number of subjects: 10
Study 7870968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine (0.5 mg/kg)
Number of subjects: 10
Study 7870968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine (1.0 mg/kg)
Number of subjects: 10
Study 7870968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 3024879 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg i.m.)
Number of subjects: 10
Study 3024879 — intervention group
Group type: COMPARATOR
Intervention: GHRH (1 microgram/kg i.v.)
Number of subjects: 10
Study 3024879 — intervention group
Group type: COMPARATOR
Intervention: TRH (300 micrograms i.v.) plus LHRH (100 micrograms i.v.) plus CRH (1 microgram/kg i.v.)
Number of subjects: 10
Study 31853550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone replacement
Number of subjects: 0
Study 31853550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucocorticoid replacement
Number of subjects: 0
Study 31853550 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium glucocorticoid replacement
Number of subjects: 0
Study 31853550 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucocorticoid replacement
Number of subjects: 0
Study 31853550 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 31853550 — intervention group
Group type: EXPERIMENTAL
Intervention: Addison's disease patients
Number of subjects: 0
Study 29987079 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the illness-focused interactive booklet
Number of subjects: 25355
Study 29987079 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no access to the booklet)
Number of subjects: 25355
Study 26852745 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg levofloxacin
Number of subjects: 12
Study 26553692 — intervention group
Group type: EXPERIMENTAL
Intervention: YF vaccine coadministered with PsA‐TT and measles vaccine
Number of subjects: 0
Study 26553692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 24078364 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent diabetes care training course
Number of subjects: 90
Study 24078364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 90
Study 20065174 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CRT with capecitabine, oxaliplatin, and concurrent radiation followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)
Number of subjects: 108
Study 20065174 — intervention group
Group type: COMPARATOR
Intervention: Induction CAPOX followed by CRT and surgery
Number of subjects: 108
Study 20065174 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant CAPOX
Number of subjects: 108
Study 19052197 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment for 8 weeks
Number of subjects: 0
Study 19052197 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the long allele of the 5-HTTLPR or the G variant of the TPH2 G-703T polymorphism
Number of subjects: 0
Study 19052197 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH2 polymorphism
Number of subjects: 0
Study 15975497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein/high carbohydrate shake (17% protein, 75% carbohydrate, 8% fat)
Number of subjects: 8
Study 15975497 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate shake (62% protein, 28% carbohydrate, 10% fat)
Number of subjects: 8
Study 15975497 — intervention group
Group type: COMPARATOR
Intervention: 100% protein shake
Number of subjects: 8
Study 15975497 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of low protein/high carbohydrate shake and high protein/low carbohydrate shake
Number of subjects: 8
Study 15975497 — intervention group
Group type: COMPARATOR
Intervention: Comparison of shakes with 100% protein shake
Number of subjects: 8
Study 15975497 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory exchange ratio over 3 h
Number of subjects: 8
Study 12357013 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised prompt
Number of subjects: 431
Study 12357013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prompt)
Number of subjects: 431
Study 10425293 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymidine phosphorylase (dThdPase) activity measured by liquid chromatography
Number of subjects: 42
Study 7483997 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoPap 300 QC System
Number of subjects: 3487
Study 7483997 — intervention group
Group type: COMPARATOR
Intervention: Cytotechnologist rescreening
Number of subjects: 3487
Study 2258519 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient education and telephone monitoring during convalescence
Number of subjects: 149
Study 2258519 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy expectations summed for all physical activities at 8 weeks
Number of subjects: 149
Study 6263072 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-bran diet (100 g of oat bran)
Number of subjects: 8
Study 6263072 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 8
Study 29605574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (500 mg capsules twice daily for 3 months)
Number of subjects: 140
Study 29605574 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg capsules twice daily for 3 months)
Number of subjects: 140
Study 31074791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (194/206mg)
Number of subjects: 19
Study 31074791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (194/206mg) combined with sitagliptin (2x100mg)
Number of subjects: 19
Study 31074791 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (2x100mg) alone
Number of subjects: 19
Study 31074791 — intervention group
Group type: COMPARATOR
Intervention: Control (standardized meal without sacubitril/valsartan)
Number of subjects: 19
Study 28261679 — intervention group
Group type: COMPARATOR
Intervention: ESWL only (Group 1)
Number of subjects: 95
Study 28261679 — intervention group
Group type: COMPARATOR
Intervention: Stenting followed by ESWL (Group 2)
Number of subjects: 95
Study 28261679 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting for 1 week followed by ESWL (Group 3)
Number of subjects: 95
Study 26421695 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 0
Study 23839228 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy (group B)
Number of subjects: 78
Study 23839228 — intervention group
Group type: COMPARATOR
Intervention: High-definition white light endoscopy (group A)
Number of subjects: 78
Study 21231791 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention including an interview about rehabilitation needs with a rehabilitation coordinator, information from the hospital to the GP about individual needs for rehabilitation, and an incentive for the GP to contact the patient.
Number of subjects: 955
Study 21231791 — intervention group
Group type: COMPARATOR
Intervention: Usual procedures (control group)
Number of subjects: 955
Study 18328518 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil/dapsone + artesunate (CD+A)
Number of subjects: 800
Study 18328518 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine+sulfadoxine/pyrimethamine (AQ+SP)
Number of subjects: 800
Study 16426473 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use scented intersurgical face mask
Number of subjects: 48
Study 16426473 — intervention group
Group type: COMPARATOR
Intervention: Single-use cushioned 7,000 series Air Safety Ltd. face mask
Number of subjects: 48
Study 16426473 — intervention group
Group type: COMPARATOR
Intervention: Reusable silicone Laerdal face mask
Number of subjects: 48
Study 16426473 — intervention group
Group type: COMPARATOR
Intervention: Reusable anatomical intersurgical face mask
Number of subjects: 48
Study 12616104 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 21
Study 12616104 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + GM-CSF (125 mcg/m)
Number of subjects: 21
Study 12616104 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + GM-CSF (250 mcg/m)
Number of subjects: 21
Study 12616104 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + GM-CSF (all doses)
Number of subjects: 21
Study 11775394 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 36
Study 11775394 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 36
Study 9279225 — intervention group
Group type: EXPERIMENTAL
Intervention: No routine in-line suction catheter changes
Number of subjects: 521
Study 9279225 — intervention group
Group type: COMPARATOR
Intervention: In-line suction catheter changes every 24 h
Number of subjects: 521
Study 9279225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 521
Study 8345498 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (4 weeks)
Number of subjects: 30
Study 8345498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (6 weeks)
Number of subjects: 30
Study 8345498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first period)
Number of subjects: 30
Study 8345498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (second period)
Number of subjects: 30
Study 3524727 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 25
Study 3524727 — intervention group
Group type: COMPARATOR
Intervention: Placebo transcutaneous nerve stimulation
Number of subjects: 25
Study 30179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiosulfate HYD 0.075 mg/cm
Number of subjects: 255
Study 30179971 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiosulfate 0.5% pet
Number of subjects: 255
Study 30179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiosulfate HYD
Number of subjects: 255
Study 26749163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCC resource pack and workshop
Number of subjects: 4
Study 26749163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCC resource pack only
Number of subjects: 4
Study 26749163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-only resource
Number of subjects: 4
Study 26749163 — intervention group
Group type: COMPARATOR
Intervention: No interventions (waitlist control)
Number of subjects: 4
Study 24906545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 TOCT sessions over 2 weeks (2 hours/each session) followed by a 3 months home exercise program
Number of subjects: 24
Study 24906545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific rehabilitation intervention)
Number of subjects: 24
Study 22426845 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 10
Study 22426845 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 10
Study 22426845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20409671 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO A allele
Number of subjects: 98
Study 20409671 — intervention group
Group type: EXPERIMENTAL
Intervention: BclI G/G genotype
Number of subjects: 98
Study 18216373 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) - Transbond Plus
Number of subjects: 37
Study 18216373 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (CM) - Transbond XT
Number of subjects: 37
Study 16172795 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h drainage
Number of subjects: 100
Study 16172795 — intervention group
Group type: COMPARATOR
Intervention: Long-term drainage
Number of subjects: 100
Study 12514683 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment in the ED by an advanced practice nurse and subsequent referral to community or social agency, primary care provider, and/or geriatric clinic for unmet health, social, and medical needs.
Number of subjects: 650
Study 12514683 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary ED care
Number of subjects: 650
Study 12514683 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment in the ED
Number of subjects: 650
Study 10795791 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g creatine + 1 g glucose x d(‐1), N = 11)
Number of subjects: 23
Study 10795791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 x 6 g glucose x d(‐1), N = 12)
Number of subjects: 23
Study 8677576 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg fleroxacin
Number of subjects: 84
Study 8677576 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous (IV) dose of 400 mg fleroxacin
Number of subjects: 84
Study 8677576 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended regimen of initial 400 mg IV dose followed by oral therapy (400 mg/day or 200 mg/day for specific patients)
Number of subjects: 84
Study 8677576 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis mentioned)
Number of subjects: 84
Study 2497545 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ASA
Number of subjects: 18
Study 2497545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ASA
Number of subjects: 18
Study 2497545 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ASA
Number of subjects: 18
Study 195201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g butylbiguanide and 1.5 g clofibrate/day
Number of subjects: 21
Study 195201 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g clofibrate/day
Number of subjects: 21
Study 30768860 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib maleate tablets (100 mg and 200 mg)
Number of subjects: 0
Study 30768860 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib maleate tablets with food (high-fat meal)
Number of subjects: 0
Study 30768860 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib maleate tablets with omeprazole
Number of subjects: 0
Study 30768860 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib maleate tablets with famotidine
Number of subjects: 0
Study 30768860 — intervention group
Group type: COMPARATOR
Intervention: Reference tablet (filgotinib hydrochloride)
Number of subjects: 0
Study 30768860 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 0
Study 30768860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-reducing agents (ARAs)
Number of subjects: 0
Study 28712478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (EMLA cream)
Number of subjects: 120
Study 28712478 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point acupressure
Number of subjects: 120
Study 28712478 — intervention group
Group type: COMPARATOR
Intervention: Control (routine prevenipuncture care)
Number of subjects: 120
Study 26401593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle
Number of subjects: 149
Study 26401593 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP
Number of subjects: 149
Study 26401593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined
Number of subjects: 149
Study 22258311 — intervention group
Group type: EXPERIMENTAL
Intervention: Single TightRope™ technique (STR)
Number of subjects: 29
Study 22258311 — intervention group
Group type: EXPERIMENTAL
Intervention: Double TightRope™ technique (DTR)
Number of subjects: 29
Study 25665209 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fox test protocol (MFT)
Number of subjects: 111
Study 25665209 — intervention group
Group type: COMPARATOR
Intervention: Direct estimation of VO2(max) via incremental bicycle exercise and expired gas analysis
Number of subjects: 111
Study 19534799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 1493
Study 19534799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg
Number of subjects: 1493
Study 19534799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg
Number of subjects: 1493
Study 19534799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study 22632587 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental stabilization exercises (SSEs)
Number of subjects: 30
Study 22632587 — intervention group
Group type: COMPARATOR
Intervention: Stretching of trunk and hamstrings muscles
Number of subjects: 30
Study 15954874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with chlorhexidine
Number of subjects: 486
Study 15954874 — intervention group
Group type: COMPARATOR
Intervention: No vaginal cleansing
Number of subjects: 486
Study 12798785 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg NaCl
Number of subjects: 80
Study 12798785 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg NaCl
Number of subjects: 80
Study 12798785 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg NaCl
Number of subjects: 80
Study 12798785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (empty capsule)
Number of subjects: 80
Study 9718051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (hormone group)
Number of subjects: 2763
Study 9718051 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 2763
Study 8124968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-limited ventilation
Number of subjects: 27
Study 8124968 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 27
Study 2530634 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 gauge needle
Number of subjects: 274
Study 2530634 — intervention group
Group type: COMPARATOR
Intervention: 23 gauge needle
Number of subjects: 274
Study 2530634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 23 gauge and 25 gauge needles
Number of subjects: 274
Study 331504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin
Number of subjects: 0
Study 331504 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 29549893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint mobilization
Number of subjects: 20
Study 29549893 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-mobilization
Number of subjects: 20
Study 29549893 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 27510498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 0
Study 27510498 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 27510498 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination task
Number of subjects: 0
Study 27510498 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 24441734 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture technique (MF)
Number of subjects: 25
Study 24441734 — intervention group
Group type: COMPARATOR
Intervention: Osteochondral autologous transplantation (OAT) mosaicplasty
Number of subjects: 25
Study 23945285 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven favorable environmental factors present
Number of subjects: 50685
Study 23945285 — intervention group
Group type: EXPERIMENTAL
Intervention: Four favorable environmental factors present
Number of subjects: 50685
Study 23945285 — intervention group
Group type: COMPARATOR
Intervention: No favorable environmental factors
Number of subjects: 50685
Study 20739426 — intervention group
Group type: EXPERIMENTAL
Intervention: VA/BC supplementation
Number of subjects: 594
Study 20739426 — intervention group
Group type: COMPARATOR
Intervention: No VA/BC supplementation (Control)
Number of subjects: 594